Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma

Matthew J Reilley,Craig L Slingluff,Osama Rahma,Victoire Cardot-Ruffino,Chee-Chee Stucky,Gina R Petroni,Scott Rodig,Matthew H G Katz,Gauri R Varadhachary,Tanios S Bekaii-Saab,Jonathan Andrew Nowak,Patrick Lenehan,Andressa Dias Costa,Rawad Elias,Kathleen Pfaff,Stephanie K Dougan,Nipun Merchant,Brian M Wolpin,Todd Bauer

doi:10.1136/jitc-2023-007586

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma

Matthew J Reilley, Craig L Slingluff + Show 17 more

Open Access

https://doi.org/10.1136/jitc-2023-007586

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Dec 1, 2023
Citations: 2	License type: CC BY-NC 4.0

Affiliation: University of Virginia Health System, Dana-Farber Cancer Institute, Harvard University, Mayo Clinic, University of Virginia, The University of Texas MD Anderson Cancer Center, Hartford Hospital, Brigham and Women's Hospital, University of Miami

#Tumor-infiltrating Lymphocyte Density #Tumor-infiltrating Lymphocyte + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundPancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall survival...

Full Text